UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 267

Sortiert nach

Effects of crushed Schisandra Fruit on the content of lignans in Kampo decoction

Journal of natural medicines, 2019-03, Vol.73 (2), p.381-387

2019

Volltextzugriff (PDF)

Abstract 1563: DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1563-1563

2021

Volltextzugriff (PDF)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Frontiers in oncology, 2022-05, Vol.12, p.869078-869078

2022

Volltextzugriff (PDF)

Binding of endostatin to human ovarian cancer cells inhibits cell attachment

International journal of cancer, 2007-12, Vol.121 (11), p.2402-2409

2007

Volltextzugriff (PDF)

Abstract 5607: Broad acting glutamine antagonism remodels the tumor microenvironment, induces distinctive immune modulation, and synergizes with immune checkpoint blockade

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5607-5607

2020

Volltextzugriff (PDF)

Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination

Cancer research (Chicago, Ill.), 2007-11, Vol.67 (22), p.10813-10822

2007

Volltextzugriff (PDF)

Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems

Molecular cancer therapeutics, 2022-10, Vol.21 (10), p.1561-1572

2022

Volltextzugriff (PDF)

Abstract 2339: Halting head & neck squamous cell carcinoma progression by broadly targeting glutamine metabolic pathways

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2339-2339

2021

Volltextzugriff (PDF)

Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor

Cancer research (Chicago, Ill.), 2019-04, Vol.79 (8), p.1996-2008

2019

Volltextzugriff (PDF)

Abstract 3027: Elucidating the role of glutamine metabolism in head & neck squamous cell carcinoma

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3027-3027

2022

Volltextzugriff (PDF)

A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death

Cancer letters, 2024-08, Vol.598, p.217089, Article 217089

2024

Volltextzugriff (PDF)

Abstract 335: In situ protein complexes as a measure of AXL signaling and inhibitor response in cell line models of lung cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.335-335

2017

Volltextzugriff (PDF)

Abstract 3767: Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3767-3767

2018

Volltextzugriff (PDF)

Combined therapy with anti-death receptor-5 antibody and triptolide induces apoptosis in pancreatic cancer cells

Journal of the American College of Surgeons, 2008, Vol.207 (3), p.S102-S102

2008

Volltextzugriff (PDF)

Silencing of heat shock factor 1: A potential therapeutic strategy for pancreatic cancer

Journal of the American College of Surgeons, 2008, Vol.207 (3), p.S21-S21

2008

Volltextzugriff (PDF)

Targeting pancreatic cancer metabolic dependencies through glutamine antagonism

Nature cancer, 2024-01, Vol.5 (1), p.85

2024

Volltextzugriff (PDF)

Abstract 4191: RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor, demonstrates efficacy in TAM-driven tumors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4191-4191

2017

Volltextzugriff (PDF)

Abstract 4698: Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4698-4698

2017

Volltextzugriff (PDF)

Abstract 3771: Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3771-3771

2018

Volltextzugriff (PDF)

Abstract LB-080: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-080-LB-080

2016

Volltextzugriff (PDF)

Abstract LB-080: Imprime PGG, a -glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-080-LB-080

2016

Volltextzugriff (PDF)

Addition of an aminopeptidase N‐binding sequence to human endostatin improves inhibition of ovarian carcinoma growth

Cancer, 2005-07, Vol.104 (2), p.321-331

2005

Volltextzugriff (PDF)

Abstract A35: Immunological characterization of Imprime PGG® and an anti-EGFR antibody combination treatment for cancer

Clinical cancer research, 2010-07, Vol.16 (14_Supplement), p.A35-A35

2010

Volltextzugriff (PDF)

Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells

JNCI : Journal of the National Cancer Institute, 2004-10, Vol.96 (19), p.1473-1477

2004

Volltextzugriff (PDF)

Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth

International journal of cancer, 2004-10, Vol.111 (6), p.839-848

2004

Volltextzugriff (PDF)

1 – 25 von 267

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(227)
Mit Volltextzugriff
(256)

Publikationsform

Artikel
(266)
Berichte
(1)

Sprache

Englisch
(235)
Japanisch
(114)

Erscheinungsjahr

n.n

Thema

Science & Technology
(143)
Life Sciences & Biomedicine
(115)
Humans
(80)
Female
(49)
Male
(44)
Animals
(33)
Biological And Medical Sciences
(32)
Middle Aged
(29)
Medical Sciences
(25)
Oncology
(24)
Physical Sciences
(22)
Adult
(21)
Mice
(21)
Aged
(16)
Endocrinology & Metabolism
(14)
Biochemistry & Molecular Biology
(12)
Chemistry
(12)
Japan
(12)
Japan - Epidemiology
(11)
Science & Technology - Other Topics
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Effects of crushed Schisandra Fruit on the content of lignans in Kampo decoction

Abstract 1563: DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

Binding of endostatin to human ovarian cancer cells inhibits cell attachment

Abstract 5607: Broad acting glutamine antagonism remodels the tumor microenvironment, induces distinctive immune modulation, and synergizes with immune checkpoint blockade

Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination

Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems

Abstract 2339: Halting head & neck squamous cell carcinoma progression by broadly targeting glutamine metabolic pathways

Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor

Abstract 3027: Elucidating the role of glutamine metabolism in head & neck squamous cell carcinoma

A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death

Abstract 335: In situ protein complexes as a measure of AXL signaling and inhibitor response in cell line models of lung cancer

Abstract 3767: Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Combined therapy with anti-death receptor-5 antibody and triptolide induces apoptosis in pancreatic cancer cells

Silencing of heat shock factor 1: A potential therapeutic strategy for pancreatic cancer

Targeting pancreatic cancer metabolic dependencies through glutamine antagonism

Abstract 4191: RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor, demonstrates efficacy in TAM-driven tumors

Abstract 4698: Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor

Abstract 3771: Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development

Abstract LB-080: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

Abstract LB-080: Imprime PGG, a -glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

Addition of an aminopeptidase N‐binding sequence to human endostatin improves inhibition of ovarian carcinoma growth

Abstract A35: Immunological characterization of Imprime PGG® and an anti-EGFR antibody combination treatment for cancer

Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells

Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth

Suchergebnisse filtern